Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
VIP (Vasoactive Intestinal Peptide) (VIP) is a research peptide, at the preclinical stage in the published literature. Neuropeptide with wide-ranging effects on the nervous system, immune function, and circadian rhythm.
Neuropeptide with wide-ranging effects on the nervous system, immune function, and circadian rhythm.
| Research Status | Preclinical |
|---|---|
| Half-Life | ~2 minutes |
| Administration | Intranasal or subcutaneous |
| Doses Reported in Published Studies | 50-100 mcg intranasal |
Activates VPAC1 and VPAC2 receptors throughout the body for multiple physiological effects.
Neuropeptide with wide-ranging effects on the nervous system, immune function, and circadian rhythm.
Activates VPAC1 and VPAC2 receptors throughout the body for multiple physiological effects.
VIP (Vasoactive Intestinal Peptide) is at the following stage in the published literature: Preclinical. All information is for research and educational purposes only.
Reported half-life: ~2 minutes.
Reported administration route in the literature: Intranasal or subcutaneous. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.